Janney Montgomery Scott LLC Acquires Shares of 4,946 Humana Inc. (NYSE:HUM)

Janney Montgomery Scott LLC acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,946 shares of the insurance provider's stock, valued at approximately $1,309,000.

Other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in Humana by 7.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider's stock valued at $244,811,000 after purchasing an additional 65,735 shares during the last quarter. denkapparat Operations GmbH bought a new position in Humana in the 4th quarter valued at $323,000. Allstate Corp bought a new position in Humana in the 4th quarter valued at $905,000. Deutsche Bank AG raised its position in Humana by 18.2% in the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock valued at $160,185,000 after purchasing an additional 97,071 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in Humana in the 4th quarter valued at $14,097,000. Institutional investors own 92.38% of the company's stock.

Humana Stock Up 0.8%

NYSE:HUM opened at $241.82 on Friday. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The stock has a market cap of $29.18 billion, a price-to-earnings ratio of 17.10, a PEG ratio of 1.82 and a beta of 0.43. The stock has a 50-day moving average price of $241.94 and a two-hundred day moving average price of $259.30.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same period in the previous year, the firm earned $7.23 earnings per share. The company's revenue was up 8.4% on a year-over-year basis. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.46%. Humana's dividend payout ratio is currently 25.04%.

Analysts Set New Price Targets

HUM has been the subject of a number of recent research reports. Oppenheimer boosted their target price on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Guggenheim initiated coverage on Humana in a research report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price objective for the company. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Mizuho lifted their price objective on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Finally, Truist Financial set a $280.00 price objective on Humana and gave the stock a "hold" rating in a research report on Tuesday, June 17th. Sixteen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Humana presently has a consensus rating of "Hold" and an average price target of $280.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.